TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (age ≥18 years), male or female.~* American Society of Anesthesiology (ASA) status I to III.~* Able to read and understand the information sheet~* Subjects who have signed and dated the consent form.~* Scheduled for elective surgery.~* If the patient is female and of childbearing potential, she must have a negative pregnancy test (serum hCG or urine dipstick).~Exclusion criteria:~* A history of allergy or hypersensitivity to dexamethasone or any component of its formulation.~* Hepatic dysfunction\* (i.e bilirubin \<1.5 upper limit normal (ULN), alanine aminotransferase (ALT) \<2.5 x ULN, aspartate aminotransferase (AST) \<2.5 x ULN).~* Renal insufficiency\* (i.e. creatinine \<1.5 x ULN, creatinine clearance \<30ml min-1).~* Pregnant, or intending to become pregnant, women.~* Breastfeeding women.~* Patient having used any investigational drug within 30 days of screening.~* Patient having participated in any clinical trial within 30 days.~* Patients with active GI ulcer.~* Patients needing prolonged postoperative intubation.~* Patients needing a gastric tube postoperatively.~* Patients receiving antiemetic drugs (butyrophenones, 5-HT3 receptor antagonists, dexamethasone).~* Patients taking drugs that interfere with platelet aggregation (for instance, aspirine or clopidogrel) within seven days preoperatively.~* Patients with overt psychosis or taking antipsychotic treatment (for instance, anti-dopaminergic drugs).~* Patients taking drugs with known emetogenic potency (for instance, L-Dopa, COMT inhibitors).~* Specific types of surgery: tonsillectomy (increased risk of postoperative bleeding), interventions that require strict prevention of postoperative vomiting.~* Systemic infections (bacterial, fungal, malaria, viral, tuberculosis).~* Local infections (for instance, ocular herpes simplex).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injection of Placebo (Type: PLACEBO_COMPARATOR): Intravenous Saline 0.9% 10 ml
- Dexamethasone 3 mg (Type: ACTIVE_COMPARATOR): Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
- Dexamethasone 6 mg (Type: ACTIVE_COMPARATOR): Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
- Dexamethasone 12 mg (Type: ACTIVE_COMPARATOR): Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PTNS for Female Patients Suffering From Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with diagnosis for Multiple Sclerosis (Clinically isolated syndrome (CIS), relapsing remitting (RRMS), secondary progressive (SPMS), and/or primary progressive (PPMS)), 18 years of age or older~* Self-reported bladder symptoms \> 3 months~* Discontinued antimuscarinics/beta-3 agonists for \> 2 weeks, and remain off for the duration of the study~* Capable of giving informed consent~* Ambulatory and able to use toilet independently without difficulty~* Capable and willing to follow all study-related procedures~* If of childbearing age, agree to practice approved birth-control methods (oral contraceptives, condom barrier, injection, diaphragm or cervical cap, vaginal contraceptive ring, intrauterine device (IUD), implantable contraceptive, surgical sterilization (bilateral tubal ligation), vasectomized partner(s))~* Subject agrees not to start any new treatments for urinary symptoms (medication or otherwise) during the treatment and follow-up periods.~* Subject agrees to maintain a stable dose on all current medications throughout the treatment and follow-up period.~Exclusion Criteria:~* Pregnant or planning to become pregnant during study duration~* Botox (BTX) use in bladder or pelvic floor muscles within past 6 months~* Pacemakers or implantable defibrillators~* Current urinary tract infection~* Active use of neuromodulation in any other form. If patient has InterStim, must be turned off for 2 weeks for a washout period and remain off during the entirety of the study.~* Current use of Transcutaneous Electrical Nerve Stimulation (TENS) in pelvic region, back or legs~* Previous PTNS treatment~* Participation in any clinical investigation involving or impacting gynecologic, urinary, or renal function within past 4 weeks~Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active PTNS (Type: ACTIVE_COMPARATOR): Once a week induction consisting of active PTNS treatments for 30 minutes for 12 consecutive weeks.
- Sham PTNS (Type: PLACEBO_COMPARATOR): Once a week induction consisting of Sham PTNS treatments for 30 minutes for 12 consecutive weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with knee pain for more than 2 months without significant trauma (only the index knee will be included)~2. MRI-confirmed medial meniscus lesion (patients with a medial meniscus lesion AND a lateral lesion will also be included)~3. Age 35-55 years\*~4. Eligible for outpatient surgery - ASA score 1-2~Exclusion Criteria:~1. Patients in need of acute surgery e.g. locking knees, high-energy trauma~2. Symptoms associated with other musculoskeletal co-morbidities overriding the symptoms of the knee~3. Grade 3 or 4 knee OA on the Kellgren-Lawrence classification~4. Knee surgery within the last 2 years~5. Obese patients with BMI \> 35~6. Patients with ischemic heart disease~7. Patients with diabetic late-complications~8. Patients with thrombophilia~9. Pregnancy~10. Patients unable to speak Danish~11. Patients with drug or alcohol abuse

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- APM group (Type: EXPERIMENTAL): None
- Sham group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bladder pain / suprapubic pressure or discomfort for \>6months~* Urgency/urgency incontinence and/or frequency for \>6months~* Written informed consent (including confirmation that the partner will also be treated and that during the treatment period sexual intercourse is only allowed using condoms)~Exclusion Criteria~* age \< 18 years~* Tetracycline allergy~* Intake of a tetracycline in the last 3 months~* pregnancy~* breast feeding~* bacterial cystitis in the last 4 weeks~* urethral/vaginal/cervical/uterine and/or rectal cancer~* chemical cystitis~* tuberculous cystitis~* benign or malignant bladder tumors~* Lack of radiologic exclusion of pelvic pathology

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- doxycycline (Type: ACTIVE_COMPARATOR): Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
- placebo (Type: PLACEBO_COMPARATOR): Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ssTAP vs TAP Catheters in TAH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo total abdominal hysterectomy~* Age ≥ 18 years.~* American Society of Anesthesiologists (ASA) physical status ≤ 3~Exclusion Criteria:~* Known coagulopathy~* Known allergy to Bupivacaine or morphine~* Contraindication to Tylenol usage~* Medical conditions contraindicated to bupivacaine use~* Daily narcotic usage for ≥ 2 weeks of 20mg of oxycodone daily or an equivalent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wound Infiltration (Type: PLACEBO_COMPARATOR): 0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
- TAP Blocks (Type: EXPERIMENTAL): 20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
- TAP Catheters (Type: EXPERIMENTAL): 20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Pain Memory Among Former Burned: Exploration of fMRI.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For control group:~* Affiliated or entitled to a social security~* Have signed consent before their participation in the study~* Adult women and men french and is right handed~* Vision and hearing normal or corrected~For former burned:~* Affiliated or entitled to a social security~* Have signed consent before their participation in the study~* Adult women and men french and is right handed~* Vision and hearing normal or corrected~* Localized burn at the hand or feet onset between 12 and 24 years~* Not sequelae painful at the inclusion~* Scope and depth of the burn according to classifications CIM 10~Exclusion Criteria:~For control group:~* Any contraindications to pass an fMRI test~* Neuropathic pains and psychiatric disorders~* Medical history of head injuries~* Burn presence~For former burned:~* Any contraindications to pass an fMRI test~* Neuropathic pains and psychiatric disorders~* Medical history of head injuries

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- patients (Type: EXPERIMENTAL): Patient who was burned will have fMRI.
- control group (Type: ACTIVE_COMPARATOR): Healthy volunteers (control group) will have fMRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant females, age 21-39, who received either Neevo®/NeevoDHA® or another standard prenatal vitamin (Prenatal vitamins must contain ≤1 mg folic acid, 27-35mg iron, and ≤12mcg vitamin B12).~* Clinical diagnosis of pregnancy must have been made at ≤12 weeks of Pregnancy, and delivery must have occurred on or after January 1, 2008 and on or before March 31, 2010~* Subjects must have been compliant in taking Neevo®/NeevoDHA® or other prenatal vitamin~Exclusion Criteria:~* Subjects should not have taken Prenate®, Prenate®DHA, or Prenate® Elite, which are L-methylfolate-containing prenatal vitamins.~* The following supplements within 2 months of diagnosis of pregnancy: B12 injection; \> 35mg Iron; \> 1.2 mg of folate; or a L-methylfolate product that is not a prenatal vitamin such as Life Extension methylfolate, Prothera methylfolate, Thorne 5-MTHF, Metanx®, Deplin®, Cerefolin®, or CerefolinNAC®~* History of leukemia or any anemia other than iron deficiency anemia or;~* Taking any iron supplement (in addition to the prenatal vitamin) prior to Week 22

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- Arm #1 (Test Group) (Type: None): 100 subject administered Neevo® or NeevoDHA® daily
- Arm #2 (Control group) (Type: None): 100 subject administered a prenatal vitamin daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patient Selection~1. Availability of a HLA compatible sibling donor~2. Age \>18 years~3. Myelodysplastic Syndromes with IPSS Intermediate-2 or High.~4. Poor risk acute myeloid leukaemia, de novo or transformed from MDS~5. Ineligibility for standard conditioning allograft due to age or co-existing morbidities~Donor selection~1. Related donors compatible for HLA-A, B, C, DRB1 and DQB1 by molecular typing.~Exclusion Criteria:~Patient selection~1. Cardiac insufficiency requiring treatment or symptomatic coronary artery disease.~2. Hepatic disease, with AST \> 2 times normal.~3. Severe hypoxaemia, pO2 \< 70 mm Hg, with decreased DLCO \< 70% of predicted; or mild hypoxemia, pO2 \< 80 mm Hg with severely decreased DLCO \< 60% of predicted.~4. Impaired renal function (creatinine \> 2 times upper limit of normal or creatinine clearance \< 50% for age, gender, weight).~5. Patients who have received previous treatment with Thymoglobuline~6. HIV-positive patients.~7. Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants.~8. Life expectancy severely limited by diseases other than MDS or MPD.~9. Serious concurrent untreated infection~10. Patients with limited life expectancy for other reasons~11. Serious psychiatric/ psychological disorders~12. Absence of /inability to provide informed consent~Donor selection~1. Age \>75 years, unless independently assessed to be medically fit to donate~2. Donors who for any reason are unable to tolerate the leukapheresis procedure and cannot undergo anaesthesia for marrow harvest.~3. Donors who are HIV-positive, or hepatitis B or C PCR positive.~4. Donors who are medically unsuitable to donate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FBATG (Type: EXPERIMENTAL): Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of localized prostate cancer~  * Diagnosed within the past 6 months~ * T1 or T2 disease~ * Gleason score 5-8~ * Prostate-specific antigen no greater than 20 ng/mL~* Radical prostatectomy planned~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* More than 2 years~Hematopoietic~* Hemoglobin greater than 9.0 g/dL~* Platelet count greater than 100,000/mm\^3~* Absolute neutrophil count greater than 1,000/mm\^3~Hepatic~* SGPT and SGOT less than 3 times normal~* Bilirubin less than 3 mg/dL (less than 1.5 times normal) (patients with an elevated bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)~Renal~* Creatinine less than 2.0 mg/dL~Cardiovascular~* No venous thrombosis within the past year~Other~* Patients must use effective barrier contraception~* No other medical condition that would preclude study therapy~* No known soy intolerance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* No concurrent hormonal therapy for prostate cancer~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~Other~* No concurrent soy supplements~* No concurrent foods high in genistein~* No concurrent active therapy for neoplastic disorders

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
- Group B (Type: EXPERIMENTAL): Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Analysis of Liver Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:3.1.1 Male or female patients 18 years of age and above. 3.1.2 Patients diagnosed with liver cancer based on biopsy or serum alpha-fetoprotein level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. Patients with metastatic tumor from anther organ, such as metastatic colon cancer.~3.13 Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:3.2.1Female patients who are pregnant or nursing will be excluded from the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, 18 to 65 years of age, inclusive~* A current primary diagnosis of OAB~* Idiopathic detrusor overactivity, demonstrated by a urodynamic observation~* Evidence of frequency in combination with urinary urgency~* Written informed consent form~* Willingness to avoid pregnancy and practice adequate birth control~* Negative serum pregnancy test~* Agrees to refrain from blood donation during the course of the study~Exclusion Criteria:~* Subjects who are pregnant or lactating~* Clinically significant abnormality or clinically significant unstable medical condition~* QTc interval of 470 msec or greater at Visit 1~* Predominant stress urinary incontinence versus urge urinary incontinence based on subject history~* Neurogenic bladder (e.g. associated with spinal cord injury, multiple sclerosis, etc.)~* Anatomic or structural abnormalities possibly causing urinary incontinence or urgency, including but not limited to urogenital prolapse stage 2 or more according to the Pelvic Organ Prolapse Quantification (POP-Q) system~* Urological or gynecological surgery within 3 months of the baseline urodynamic assessment~* Current UTI or frequent UTIs (i.e., greater than or equal to 4 UTIs per year), interstitial cystitis, hematuria of unknown cause, or use of indwelling catheter~* Electro-stimulation therapy, bladder training, or physiotherapy for bladder control within 2 weeks of Visit 1~* History (within 1 year of Screening) of alcohol or substance dependence (except nicotine dependence) according to DSM-IV-TR criteria~* History of any kind of cancer within the last 2 years~* Existing non-malignant tumors that could compromise the function and/or anatomy of the lower urinary tract

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues